Evidence map›Paper›PMID 39746719›Full record

ArticleGenome research2025

Identification of the shortest species-specific oligonucleotide sequences.

Ioannis Mouratidis, Maxwell A Konnaris, Nikol Chantzi, Candace S Y Chan, Michail Patsakis, Kimonas Provatas, Austin Montgomery, Fotis A Baltoumas, Congzhou M Sha, Manvita Mareboina and 3 more

Abstract read
In one paragraph

Article in Genome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. The topography of nullomer-emerging mutations and their relevance to human disease.Computational and structural biotechnology journal · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ioannis Mouratidis *Institute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Maxwell A Konnaris *Institute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Nikol Chantzi *Institute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Candace S Y Chan *Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California 94143, USA.ORCID 0000-0001-9667-7996
Michail PatsakisInstitute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Kimonas ProvatasInstitute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Austin MontgomeryInstitute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Fotis A BaltoumasInstitute for Fundamental Biomedical Research, BSRC "Alexander Fleming," Vari 16672, Greece.
Congzhou M ShaInstitute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.ORCID 0000-0001-5301-9459
Manvita MareboinaInstitute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Georgios A PavlopoulosInstitute for Fundamental Biomedical Research, BSRC "Alexander Fleming," Vari 16672, Greece.
Dionysios V ChartoumpekisService of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, 1005 Lausanne, Switzerland.
Ilias Georgakopoulos-SoaresInstitute for Personalized Medicine, Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA; ipm5219@psu.edu izg5139@psu.edu.ORCID 0000-0003-3641-1488

Funding

Harnessing the Power of Kmers: Concepts and Methods for Genomic and Proteomic ResearchR35GM155468 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Ilias Georgakopoulos-Soares · 2024 to 2026
$1.2M
NIGMS NIH HHS R35 GM155468
6 · The paper itself

Abstract

Despite the exponential increase in sequencing information driven by massively parallel DNA sequencing technologies, universal and succinct genomic fingerprints for each organism are still missing. Identifying the shortest species-specific nucleotide sequences offers insights into species evolution and holds potential practical applications in agriculture, wildlife conservation, and healthcare. We propose a new method for sequence analysis termed nucleic "quasi-primes," the shortest occurring sequences in each of 45,076 organismal reference genomes, present in one genome and absent from every other examined genome. In the human genome, we find that the genomic loci of nucleic quasi-primes are most enriched for genes associated with brain development and cognitive function. In a single-cell case study focusing on the human primary motor cortex, nucleic quasi-prime genes account for a significantly larger proportion of the variation based on average gene expression. Nonneuronal cell types, including astrocytes, endothelial cells, microglia perivascular-macrophages, oligodendrocytes, and vascular and leptomeningeal cells, exhibit significant activation of quasi-prime-containing gene associations related to cancer, whereas simultaneously suppressing quasi-prime-containing genes are associated with cognitive, mental, and developmental disorders. We also show that human disease-causing variants, eQTLs, mQTLs, and sQTLs are 4.43-fold, 4.34-fold, 4.29-fold, and 4.21-fold enriched at human quasi-prime loci, respectively. These findings indicate that nucleic quasi-primes are genomic loci linked to the evolution of species-specific traits, and in humans, they provide insights in the development of cognitive traits and human diseases, including neurodevelopmental disorders.

Indexed as

OligonucleotidesSequence Analysis, DNAAnimalsGenome, HumanGenomicsHigh-Throughput Nucleotide SequencingHumansQuantitative Trait LociSpecies SpecificityOligonucleotides

Identifiers

PMID39746719
PMCPMC11874967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.